Piper Sandler raised the firm’s price target on Arrowhead (ARWR) to $110 from $100 and keeps an Overweight rating on the shares. The firm notes Arrowhead launched Redemplo for familial chylomicronemia syndrome, and it conservatively forecasts sales of $8.4M in FY26 to grow to $41.6M in FY27. Piper is confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in Q3 2026 with potential blockbuster label expansion in 2027.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals Issues Zero-Coupon 2032 Convertible Notes
- Arrowhead’s ARO-DIMERPA Trial Advances in Mixed Hyperlipidemia: What Investors Should Watch
- Arrowhead Pharmaceuticals Launches Major Equity and Notes Offerings
- Arrowhead 3.1M share Secondary priced at $64.50
- Arrowhead announces China NMPA approval for Redemplo